Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical, a company that produces, developes, and markets generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, has reported net sales of $3.8bn for the second quarter ended June 30, 2010, an increase of 12%, compared to $3.4bn for the comparable period in 2009.
Subscribe to our email newsletter
Teva Pharma has posted a net income of $800m for the second quarter 2010, or $ 0.88 per diluted share, compared to $523m or $0.58 per diluted share for the comparable period in 2009. Operating income was $1bn compared to $702m for the comparable period in 2009.
For the six months ended June 30, 2010, the company has posted a net income of $1.5bn, or $1.66 per diluted share compared to $974m, or $1.09 per diluted share for the year ago period.
Shlomo Yanai, president and CEO of Teva Pharma, said: “It was an especially strong quarter in North America, where we had nine new product launches, and in Europe, where we experienced growth.”